Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Management and Research"
DOI: 10.2147/cmar.s400013
Abstract: Abstract Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin’s lymphoma (NHL). 30 ~ 40% of DLBCL patients were resistant to the standard R-CHOP regimen or recurrence after remission. It is currently believed… read more here.
Keywords: refractory dlbcl; drug; resistance mechanism; drug resistance ... See more keywords